Current Treatment Options for Primary Biliary Cholangitis

Kimberly A. Wong; Runalia Bahar; Chung H. Liu; Christopher Bowlus

doi:10.1016/j.cld.2018.03.003

Current Treatment Options for Primary Biliary Cholangitis

Kimberly A. Wong, Runalia Bahar, Chung H. Liu, Christopher Bowlus

Gastroenterology and Hepatology

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.

Original language	English (US)
Journal	Clinics in Liver Disease
DOIs	https://doi.org/10.1016/j.cld.2018.03.003
State	Accepted/In press - Jan 1 2018

Keywords

Autoimmune liver disease
Bile acids
Farnesoid X receptor
Therapy

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2018.03.003

Fingerprint Dive into the research topics of 'Current Treatment Options for Primary Biliary Cholangitis'. Together they form a unique fingerprint.

Cite this

Wong, K. A., Bahar, R., Liu, C. H., & Bowlus, C. (Accepted/In press). Current Treatment Options for Primary Biliary Cholangitis. Clinics in Liver Disease. https://doi.org/10.1016/j.cld.2018.03.003

@article{661548c53efb4bdc8f0ff27bda6774c2,

title = "Current Treatment Options for Primary Biliary Cholangitis",

abstract = "Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.",

keywords = "Autoimmune liver disease, Bile acids, Farnesoid X receptor, Therapy",

author = "Wong, {Kimberly A.} and Runalia Bahar and Liu, {Chung H.} and Christopher Bowlus",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/j.cld.2018.03.003",

language = "English (US)",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Current Treatment Options for Primary Biliary Cholangitis

AU - Wong, Kimberly A.

AU - Bahar, Runalia

AU - Liu, Chung H.

AU - Bowlus, Christopher

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.

AB - Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.

KW - Autoimmune liver disease

KW - Bile acids

KW - Farnesoid X receptor

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85047222695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047222695&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2018.03.003

DO - 10.1016/j.cld.2018.03.003

M3 - Article

C2 - 30259848

AN - SCOPUS:85047222695

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

ER -